

25 February 2021

ReNeuron Group plc
("ReNeuron" or the "Company")

Investor presentations

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces it will be presenting at three investor events, providing an overview of the business and the progress being made by the Company as it focuses on its retinal disease programme and exosome and iPSC platforms.

Proactive One2One Investor Forum

ReNeuron will present at today's Proactive One2One Investor Forum, commencing at 6.00pm, with ReNeuron presenting at this time. The event brings together high net worth investors and private investors with an interest in growth stocks. Investors can register to attend the event here:

https://www.proactiveinvestors.co.uk/register/event_details/319

Shares Investor Evening Webinar

ReNeuron will present at the Shares Investor Evening Webinar, on Tuesday 2 March 2021. Shares Spotlight webinars feature presentations from directors of listed companies explaining their investment propositions followed by an opportunity for investors to ask questions. The event will commence at 6.00pm and ReNeuron will present at 6.55pm. Investors can register to attend the event here: <https://www.sharesmagazine.co.uk/events/event/shares-investor-evening--webinar-020321>

H.C. Wainwright Global Life Sciences Conference

The Company will present at the H.C. Wainwright Global Life Sciences Virtual Conference which is taking place on 9-10 March 2021. The conference will consist of panel discussions, company presentations, virtual events, and networking opportunities. The presentation will be available on demand during the conference. Investors can register for the conference here: <https://hcwevents.com/globalconference/#toggle-id-1-closed>

No new material information will be disclosed, and the presentations will be made available on the Company website shortly after the events here: <http://www.reneuron.com/investors/presentations/>

Contacts:

ReNeuron

Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer

www.reneuron.com/investors

Via Walbrook PR

Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

Ben Maddison, Stewart Wallace

+44 (0)20 7710 7600

Allenby Capital Limited (Joint Broker)

James Reeve/George Payne (Corporate Finance)
Tim Sohal (Sales & Corporate Broking)

+44 (0)20 3328 5656

Walbrook PR (Media & Investor Relations)

Paul McManus, Alice Woodings

+44 (0)20 7933 8780 or reneuron@walbrookpr.com

+44 (0)7980 541 893 / +44 (0)7407 804 654

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com